Pharmaceutical giant Sanofi (SNY -0.95%) and biotech Regeneron (REGN -0.47%) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (AMGN 0.76%) and Pfizer's (PFE -0.79%) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.